Consent given pursuant to sections 14 and 14A for the importation and supply of the therapeutic goods specified - Takeda Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and importation of therapeutic goods in Australia, ensuring they meet quality, safety, and efficacy standards. This Act provides a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood products, by establishing controls over their manufacture, supply, and advertising. The Therapeutic Goods Act 1989 was introduced to address the need for a cohesive and effective regulatory system that safeguards public health by ensuring that therapeutic goods available in Australia are of acceptable quality and meet prescribed standards. Enacted by the Australian Parliament, the policy objective of the Act is to protect and promote public health by controlling the quality and safety of therapeutic goods, and ensuring their appropriate use. On 15 January 2015, the delegate of the Secretary of the Department of Health granted consent for the importation and supply of specific pioglitazone products under Section 14 and 14A of the Therapeutic Goods Act 1989. This consent was provided to Takeda Pharmaceuticals Australia Pty Ltd for batches of ACTOS 15mg, 30mg, and 45mg tablets, which did not conform to certain labelling requirements. The consent was granted subject to conditions, including the use of previously approved labels and the arrangement for correspondence concerning the products to be referred to Takeda Pharmaceuticals Australia Pty Ltd. This action underscores the Therapeutic Goods Administration's role in facilitating the availability of necessary therapeutic goods while maintaining regulatory standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods including medicines, medical devices, blood and tissues, and therapeutic goods advertising. The Act provides a regulatory framework to ensure that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. It applies to individuals and entities involved in the manufacturing, importing, supplying, and advertising of therapeutic goods within Australia. The Act's jurisdictional reach is national, with the Therapeutic Goods Administration (TGA) being the regulatory body responsible for its enforcement across the Commonwealth. There are certain exclusions and exemptions provided under the Act, such as for goods used for personal use or for research purposes. The Act also provides for the creation of subordinate instruments, which may extend or restrict its application, such as therapeutic goods regulations that provide more detailed requirements for specific types of goods. In the specific case outlined, the Therapeutic Goods Act 1989 was invoked to allow the importation and supply of certain batches of pioglitazone tablets by Takeda Pharmaceuticals Australia Pty Ltd. These batches do not conform to certain labelling requirements as specified in the Therapeutic Goods Order No. 69. The consent granted under the Act is specific to these particular batches and includes conditions to ensure that the transition from the previous sponsor, Eli Lilly Australia Pty Ltd, to Takeda Pharmaceuticals Australia Pty Ltd is managed effectively, with proper referral of correspondence and no other changes to the product. This consent is a clear example of the Act's flexibility in allowing specific exceptions to regulatory requirements to facilitate the availability of therapeutic goods while maintaining overall safety and quality standards.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) is a crucial piece of legislation governing the regulation of therapeutic goods in Australia. Section 14 and 14A of the Act provide the legal basis for issuing consents that allow for the importation and supply of therapeutic goods that do not fully comply with specified regulations. In this case, the delegate of the Secretary of the Department of Health has given consent (C2015G00128) for Takeda Pharmaceuticals Australia Pty Ltd to import and supply certain batches of pioglitazone tablets that do not conform to labelling requirements. The consent is limited to specific batches of pioglitazone (ACTOS) tablets, identified by their Australian Register of Therapeutic Goods (AUST R) numbers and batch numbers. Under this consent, Takeda Pharmaceuticals Australia Pty Ltd is permitted to supply pioglitazone tablets with labels that list the previous sponsor, Eli Lilly Australia Pty Ltd, instead of the current sponsor, Takeda Pharmaceuticals Australia Pty Ltd. The consent is subject to certain conditions to ensure consumer safety and proper record-keeping. These conditions include maintaining arrangements with the former sponsor for the prompt referral of any correspondence concerning the products to Takeda Pharmaceuticals Australia Pty Ltd. No other changes have been made to the product beyond the labelling issue. The Act imposes specific obligations on the parties it governs, including the requirement to comply with the therapeutic goods regulations. In this case, Takeda Pharmaceuticals Australia Pty Ltd must ensure that the consent conditions are met and that the labelling issue does not compromise the safety, quality, or efficacy of the therapeutic goods. Additionally, the company must maintain proper records and documentation to demonstrate compliance with the Act and the conditions of the consent. Failure to comply with the Act or the conditions of the consent may result in various consequences. The Therapeutic Goods Act 1989 includes provisions for both civil and criminal penalties for breaches. Civil penalties may include fines, while criminal penalties may include imprisonment, depending on the severity and intent of the breach. The specific penalties for non-compliance are determined by the courts and can vary widely based on the circumstances of each case. It is important for parties governed by the Act to be aware of their obligations and to take appropriate steps to ensure compliance to avoid potential penalties.